8-K - EyePoint Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On March 2, 2026, EyePoint, Inc. issued a press release announcing the first patients dosed in both COMO and CAPRI, the Company's Phase 3 clinical

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint, Inc. dated March 2, 2026 99.2 Investor Presentation of

Exhibits Only

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2